ExodusPoint Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
ExodusPoint Capital Management's REGN Position: Q2 2026 in Review
ExodusPoint Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 3,756 shares — an estimated $2.9M sold.
ExodusPoint Capital Management first reported a position in REGN in Q4 2018 and held it in 19 quarters. The position peaked at $53.9M in Q4 2025. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- ExodusPoint Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- ExodusPoint Capital Management sold 3,756 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.9M.
- ExodusPoint Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 19 quarters.
- ExodusPoint Capital Management's Regeneron Pharmaceuticals position peaked at $53.9M in Q4 2025.
- 1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.